



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 5/023, A61K 38/07, C07K 7/22		A1	(11) International Publication Number: WO 00/08046
			(43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/EP99/05459 (22) International Filing Date: 30 July 1999 (30.07.99) (30) Priority Data: FI98A000186 5 August 1998 (05.08.98) IT (71) Applicant (for all designated States except US): MENARINI RICERCHE S.P.A. [IT/IT]; Via Tito Speri, 10, I-00040 Pomezia (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): ALTAMURA, Maria [IT/IT]; Viale Matteotti, 54, I-50132 Florence (IT). CRISCUOLI, Marco [IT/IT]; Via degli Oleandri, 1, I-56018 Tirrenia (IT). GUIDI, Antonio [IT/IT]; Via Bronzino, 17, I-50142 Florence (IT). PERROTTA, Enzo [IT/IT]; Via Andrea del Castagno, 4, I-50132 Florence (IT). MAGGI, Carlo, Alberto [IT/IT]; Via Michelazzi, 43, I-50141 Florence (IT). (74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi, Corso di Porta Vittoria, 9, I-20122 Milan (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM			
<p style="text-align: right;">(I)</p>			
(57) Abstract			
Compounds of formula (I) and their pharmaceutically acceptable salts having antagonist action on the NK2 receptor are described. Processes for the preparation of the above said compounds and pharmaceutical preparations containing them are also described.			